Safety Profiles: The Clinical Evidence You Need
Which is Safer: Mounjaro or Wegovy for Weight Management?
When determining which is safer between Mounjaro and Wegovy, both treatments demonstrate excellent safety profiles established through comprehensive clinical trials involving thousands of participants. Wegovy (semaglutide) works as a GLP-1 receptor agonist, while Mounjaro (tirzepatide) functions as a dual GIP/GLP-1 receptor agonist, targeting two hormone pathways rather than one. Both prescription-only medicines require careful medical assessment and ongoing monitoring to ensure patient safety. The choice between these treatments depends on your individual medical history, current health status, and how your body responds to each mechanism of action.
Both treatments share similar common side effects, primarily gastrointestinal symptoms including nausea, vomiting, and diarrhoea, which typically diminish as your body adjusts during dose escalation. The safety question of which is safer—Mounjaro or Wegovy—often comes down to individual tolerance and medical factors rather than one being universally safer than the other. Your prescriber will evaluate factors such as existing medical conditions, current medications, and previous treatment responses to determine which option presents the lowest risk profile for your specific situation.
Pricing Comparison: Wegovy vs Mounjaro Treatment Costs
Understanding the cost implications helps answer which is safer for your budget when comparing Mounjaro vs Wegovy options. Wegovy pricing at EverydayMeds starts at £79.99 for the 0.25mg starter dose (weeks 1-4), progressing to £94.99 for 0.5mg, £99.99 for 1mg, £139.99 for 1.7mg, and £209.99 for the 2.4mg maintenance dose. New customers can apply discount code FIRST40 at checkout, while returning customers use code DOSE25 to access these competitive prices. Our Getting Started bundles provide convenient multi-pen supplies, such as the Intro Duo (0.25mg & 0.5mg) for £169.99, designed to support your initial treatment journey.
Mounjaro pricing follows a different structure due to its distinct dosing schedule, with six dose levels ranging from 2.5mg to 15mg. When evaluating which is safer regarding financial commitment, both treatments require ongoing prescription costs, but the specific pricing depends on your prescribed maintenance dose and treatment duration. Our clinical team can provide detailed cost comparisons during your assessment, ensuring you understand the long-term financial implications of each treatment option before making your decision.
Clinical Evidence: Which is Safer Based on Research Data?
Wegovy's safety profile is established through the comprehensive STEP clinical trial programme, with STEP 1 demonstrating safety and efficacy over 68 weeks in adults with obesity. As published by Wilding et al. in the New England Journal of Medicine (2021), participants experienced manageable side effects, with the most common being gastrointestinal symptoms that typically resolved with continued treatment. The trials monitored cardiovascular safety extensively, with the recent SELECT trial showing a 20% reduction in major cardiovascular events, suggesting potential cardiovascular benefits beyond weight management.
Mounjaro's safety data comes from the SURMOUNT trial programme, which evaluated tirzepatide specifically for weight management in adults with obesity. Both treatments demonstrate similar safety profiles, with gastrointestinal side effects being the primary concern for discontinuation. When considering which is safer—Mounjaro or Wegovy—both have received regulatory approval from the MHRA with comprehensive safety monitoring requirements, including Black Triangle status indicating additional monitoring of side effects.
How Wegovy Works: Understanding the Safety Mechanism
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a natural hormone your body produces when eating. This mechanism works by slowing gastric emptying, reducing appetite, and promoting feelings of fullness after smaller meals, which naturally leads to reduced calorie intake when combined with lifestyle changes. The once-weekly injection allows for steady medication levels, reducing the risk of dramatic blood sugar fluctuations that might occur with more frequent dosing. Wegovy's targeted approach to appetite regulation has been shown to be well-tolerated by most patients, with side effects typically diminishing as the body adjusts to treatment. The gradual dose escalation protocol—starting at 0.25mg and increasing monthly—helps minimise adverse reactions while allowing your body to adapt to the medication's effects.
Ordering Process: Safe Prescription and Delivery
EverydayMeds ensures safe access to both Wegovy and Mounjaro through our comprehensive three-minute online clinical assessment, which evaluates your medical history, current medications, and treatment suitability. Our qualified prescribers review each assessment thoroughly, typically within three working days (or 24 hours for express service), ensuring appropriate prescription decisions based on safety criteria and clinical guidelines. Once approved, your prescription-only medicine is dispensed from our GPhC-registered pharmacy (#9012878) and delivered via next-day cold-chain delivery to maintain medication integrity. All patients receive detailed administration instructions and safety information with their first order, plus ongoing access to our clinical support team for any questions or concerns. This controlled process ensures both treatments are prescribed safely and delivered securely to your door.
Storage and Practical Safety: Wegovy vs Mounjaro Advantages
Storage requirements play a crucial role in determining which is safer for practical, real-world use between Mounjaro and Wegovy. Wegovy offers a significant practical safety advantage with its ability to remain stable at room temperature (below 30°C) for up to six weeks after removal from refrigeration, compared to Mounjaro's 21-day room temperature limit. This extended stability makes Wegovy particularly suitable for frequent travelers or those with variable schedules who might face challenges maintaining strict refrigeration. Both medications use pre-filled injection pens with safety features, but Wegovy's FlexTouch pen design includes additional safety mechanisms and dose confirmation features. The longer room temperature tolerance of Wegovy reduces the risk of medication wastage due to temperature excursions, making it a more forgiving option for patients concerned about maintaining cold-chain storage. Proper storage is essential for both treatments to ensure medication safety and effectiveness throughout your treatment journey.
Which is Safer: Individual Medical Factors in Mounjaro vs Wegovy Selection
The safety comparison between Mounjaro and Wegovy ultimately depends on your individual medical profile, including existing health conditions, medication interactions, and treatment history. Patients with a history of pancreatitis, gallbladder disease, or thyroid conditions require careful evaluation to determine which treatment presents the lower risk profile. Both medications carry similar contraindications, but individual responses can vary significantly, making personalised medical assessment crucial for safety. Your prescriber will consider factors such as kidney function, cardiovascular health, and diabetes status when determining which option is safer for your specific circumstances.
Family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 represents absolute contraindications for both treatments. However, other medical factors may influence which is safer on an individual basis, such as previous GLP-1 agonist experience, current medication regimens, and lifestyle factors that might affect treatment adherence. The question of which is safer—Mounjaro or Wegovy—requires comprehensive medical evaluation rather than a universal answer, as patient safety depends on matching the right treatment to the right individual based on their unique health profile.
Complete Your Assessment: Expert Guidance on Treatment Selection
Choosing between Wegovy and Mounjaro requires expert medical guidance to ensure the safest and most effective treatment for your individual needs. EverydayMeds offers both options through our comprehensive assessment process, allowing our qualified prescribers to evaluate which treatment presents the optimal safety and efficacy profile for your circumstances. New customers can access either treatment using discount code FIRST40, while returning customers benefit from code DOSE25, with both treatments available for next-day delivery once prescribed. Our clinical team provides ongoing support throughout your treatment journey, monitoring your progress and adjusting prescriptions as needed to maintain optimal safety and effectiveness. Visit our weight loss collection at https://everydaymeds.co.uk/collections/weight-loss to begin your assessment and discover which treatment option is right for you.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
